Santen Pharmaceutical Co., Ltd.
4536.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥494,321,890 | ¥520,983,800 | ¥437,784,600 | ¥490,523,925 |
| - Cash | ¥92,997,000 | ¥94,582,000 | ¥57,903,000 | ¥83,014,000 |
| + Debt | ¥34,229,000 | ¥35,158,000 | ¥36,207,000 | ¥32,932,000 |
| Enterprise Value | ¥435,553,890 | ¥461,559,800 | ¥416,088,600 | ¥440,441,925 |
| Revenue | ¥300,004,000 | ¥301,965,000 | ¥279,037,000 | ¥266,257,000 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Gross Profit | ¥171,027,000 | ¥178,709,000 | ¥166,087,000 | ¥156,586,000 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| EBITDA | ¥68,830,000 | ¥56,457,000 | ¥14,298,000 | ¥54,524,000 |
| % Margin | 22.9% | 18.7% | 5.1% | 20.5% |
| Net Income | ¥36,247,000 | ¥26,642,000 | -¥14,948,000 | ¥27,218,000 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS Diluted | 103.68 | 72.37 | -38.6 | 67.97 |
| % Growth | 43.3% | 287.5% | -156.8% | – |
| Operating Cash Flow | ¥60,928,000 | ¥72,649,000 | ¥37,147,000 | ¥46,043,000 |
| Capital Expenditures | -¥6,662,000 | -¥10,687,000 | -¥24,588,000 | -¥35,841,000 |
| Free Cash Flow | ¥54,266,000 | ¥61,962,000 | ¥12,559,000 | ¥10,202,000 |